Sinovac

Sinovac Biotech Ltd. is a Chinese biopharmaceutical company headquartered in Beijing. Founded in 2001, the company focuses on the research, development, manufacturing, and commercialization of vaccines for human use. Sinovac's product portfolio includes vaccines for diseases such as influenza, hepatitis A, hepatitis B, and rabies.

One of Sinovac's most well-known vaccines is CoronaVac, a COVID-19 vaccine developed using an inactivated virus platform. CoronaVac received Emergency Use Authorization from the World Health Organization and has been used in numerous countries worldwide. The development and deployment of CoronaVac were significant parts of global efforts to combat the COVID-19 pandemic.

Sinovac's research and development efforts extend to other infectious diseases, with ongoing projects aimed at creating vaccines for diseases like enterovirus 71 (EV71) and pneumococcal disease. The company operates manufacturing facilities in China and has established partnerships for vaccine distribution both domestically and internationally. Sinovac's business model involves selling its vaccines to government immunization programs, as well as to private healthcare providers and institutions.